Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma

JAMA Dermatol. 2018 Nov 1;154(11):1354-1356. doi: 10.1001/jamadermatol.2018.2770.

Authors

Adrien Sanchez¹, Henri Montaudie^{1

2}, Pierre Bory³, Xavier Belgodere³, Thierry Passeron^{1

2}, Jean Philippe Lacour¹, Alexandra Picard¹

Affiliations

¹ Department of Dermatology, Archet Hospital, Nice University Hospital, Nice, France.
² INSERM, U1065, The Mediterranean Center for Molecular Medicine Team 12, Nice, France.
³ Department of Oncology, Bastia Hospital, Bastia, France.

PMID: 30326507
DOI: 10.1001/jamadermatol.2018.2770

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Antiphospholipid Syndrome / chemically induced*
Antiphospholipid Syndrome / diagnosis
Antiphospholipid Syndrome / immunology
Biopsy
Female
Humans
Melanoma / diagnosis
Melanoma / drug therapy*
Middle Aged
Neoplasm Staging*
Skin / pathology
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab